Insurance - Specialty · Financial Services
CFO
Equibles does not estimate personal net worth.
Get an email with a short summary when Enact Holdings, Inc. publishes a filing, an earnings call transcript or a press release.
Get ACT alertsDean Mitchell is recorded as CFO at Enact Holdings, Inc. (ACT). Dean Mitchell was last confirmed as Board Member at Praxis Precision Medicines, Inc. (PRAX) in a filing dated April 26, 2024. Praxis Precision Medicines, Inc. reported in an 8-K filed June 6, 2024 a re-election or new board role (Class I Director) for Dean Mitchell, on the board since at least 2020, effective June 5, 2024. Dean Mitchell has spoken on 21 earnings calls across 1 company, most recently for Enact Holdings, Inc. on November 5, 2026. Enact Holdings, Inc. is classified in the Insurance - Specialty industry within the Financial Services sector. Other leadership on record at Enact Holdings, Inc. includes Hardin Dean (CFO), Hardin Dean Mitchell (CFO), Evan S. Stolove (General Counsel) and 3 others.
“The Company's stockholders elected Dean Mitchell and Jill DeSimone to serve as Class I members of the Board of Directors of the Company (the "Board") until the Company's 2027 annual meeting of stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or removal, with the votes cast as follows:”
“We delivered another strong quarter of performance. Adjusted operating income was $164 million or $1.19 per diluted share compared to $1.12 per diluted share in the same period last year and $1.26 per diluted share in the second quarter of 2026.”
“We delivered another strong quarter of performance. Adjusted operating income was $177 million, or $1.26 per diluted share, compared to $1.15 per diluted share in the same period last year, and $1.21 per diluted share in the first quarter of 2026.”
“We began 2026 with another quarter of strong results. Adjusted operating income was $172 million or $1.21 per diluted share compared to $1.10 per diluted share in the same period last year and $1.23 per diluted share in the fourth quarter of 2025.”
“We are pleased with the very strong results we delivered in the fourth quarter of 2025, which concluded an excellent year for an Act.”
“Adjusted operating income was $166 million or $1.12 per diluted share compared to $1.16 per diluted share in the same period last year, and $1.15 per diluted share in the second quarter of 2025.”
2020-01-01–2024-04-26
Last confirmed by a filing; no departure on record
Insurance - Specialty · Financial Services
CFO
Biotechnology · Healthcare
Board Member
Since 2020-01-01, last confirmed 2024-04-26